Bioxel Pharma Inc.

Bioxel Pharma Inc.

September 21, 2007 08:30 ET

Bioxel Wins Largest Paclitaxel Order from a Leading International Pharmaceutical Company

SAINTE-FOY, QUEBEC--(Marketwire - Sept. 21, 2007) - Bioxel Pharma Inc. (TSX VENTURE:BIP), a leading manufacturer and supplier of taxane active pharmaceutical ingredients (APIs), announced today that it has won its largest paclitaxel order from a well-established multinational pharmaceutical company that is presently completing Phase III clinical trials for a paclitaxel based product. The paclitaxel sale was valued at about $800,000. Paclitaxel deliveries under the order will be completed in October 2007, with repeat orders expected from the same client in the coming months.

Bioxel's paclitaxel will be incorporated in the client's New Drug Application, allowing its use in commercial manufacturing and distribution once the product has obtained marketing approval. Bioxel estimates that after initial market penetration of this new product for its primary indication in the US market alone, the paclitaxel volume requirements could be in excess of 50 kg annually. Steady sales and volumes for this customer are expected to begin in 2008, in preparation for commercial launch of its NDA product.

"This was a very important win for Bioxel on many levels," said Pascal Delmas, President and CEO of Bioxel Pharma. "This represents repeat business with a customer that has used our paclitaxel product in its previous clinical development. It validates the quality and consistency of our product and the faith that our customers have in Bioxel's ability to deliver on an ongoing commercial basis. Bioxel has proven that it can compete in this market and differentiate itself by offering the highest quality paclitaxel API together with superior customer and regulatory services." Mr. Delmas added, "We have implemented an aggressive marketing push over the past 18 months and this has begun to pay off with substantial orders. We remain committed to the growth of our paclitaxel franchise through customer diversification in both generic and next generation products, as well as through steady geographic expansion."


Bioxel Pharma Inc. is an emerging leader in biopharmaceuticals, focused on developing, manufacturing and marketing taxane pharmaceutical ingredients. Taxanes are used in drug products for the treatment of cancer and other diseases, including psoriasis, rheumatoid arthritis, Alzheimer's disease and cardiovascular disease. The Corporation sells cGMP paclitaxel and develops a portfolio of other generic taxane APIs and taxane-based proprietary products for improved cancer therapy.

This announcement includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect future results. These include risks and uncertainties that could affect Bioxel's products under development such as regulatory factors, technological developments and competitive factors. Achievement of the objectives set forth in this release is subject to these risks and uncertainties. The Corporation's results, or the measures it adopts, could differ materially from those indicated or underlying these statements, or could have an impact on the realization of financial projections.

The TSX Venture Exchange has not reviewed the contents of this press release and accepts no responsibility for the adequacy or the accuracy thereof.

Contact Information